Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Perin, E. C.
Right arrow Articles by Silva, G. V.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Perin, E. C.
Right arrow Articles by Silva, G. V.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The European Society of Cardiology 2006. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Stem cell therapy in end-stage ischaemic heart failure: a catheter-based therapeutic strategy targeting myocardial viability

Emerson C. Perin* and Guilherme V. Silva

Department of Adult Cardiology, Texas Heart Institute, St. Luke's Episcopal Hospital, 6624 Fannin, Suite 2220, Houston, TX 77030, USA

* Corresponding author. Tel: +1 713 791 9400; fax: +1 713 795 5651. E-mail address: eperin{at}crescentb.net

Recent evidence that the adult heart can repair itself through the proliferation of cardiac precursor cells and the recruitment and engraftment of bone marrow-derived precursor cells has stimulated interest in stem cell therapy for cardiac diseases. Although preclinical studies have shown the efficacy of stem cell treatment, numerous controversies exist, and many basic questions still await answers. Meanwhile, clinical trials of stem cell therapy continue to advance. Our group has focused on using stem cells to treat patients with end-stage ischaemic heart failure who are ineligible for surgical or percutaneous revascularization. The preliminary results of the phase I trial are encouraging but need to be reproduced before larger randomized trials can be attempted. This review covers some of the most important clinical developments in targeted, transendocardially delivered stem cell therapy for end-stage ischaemic heart failure.

Key Words: Stem cell therapy • Cardiac • Ischaemic heart failure • Myocardial viability • Transendocardial stem cell delivery • Bone marrow-derived mononuclear cells • Electromechanical mapping


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.